Join

Compare · CGC vs ONCR

CGC vs ONCR

Side-by-side comparison of Canopy Growth Corporation (CGC) and Oncorus Inc. (ONCR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CGC and ONCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • CGC is the larger of the two at $2.86B, about 34.8x ONCR ($82.3M).
  • CGC has hit the wire 4 times in the past 4 weeks while ONCR has been quiet.
  • CGC has more recent analyst coverage (19 ratings vs 0 for ONCR).
MetricCGCONCR
Company
Canopy Growth Corporation
Oncorus Inc.
Price
$1.02+0.00%
$0.12-10.15%
Market cap
$2.86B
$82.3M
1M return
-9.29%
-
1Y return
-31.67%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
4
0
Recent ratings
19
0
CGC

Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

ONCR

Oncorus Inc.

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest CGC

Latest ONCR